| DrugRepV_0262 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | TCID50 assay | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0263 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | TCID50 assay | Decrease (~20 Fold) | Approved | 27466418 |
| DrugRepV_0264 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | TCID50 assay | Decrease (>10 Fold) | Approved | 27466418 |
| DrugRepV_0265 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | TCID50 assay | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0266 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0267 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | MA15 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0268 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Real-time PCR | Decrease (>100 Fold) | Approved | 27466418 |
| DrugRepV_0269 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Real-time PCR | Decrease (>10 Fold) | Approved | 27466418 |
| DrugRepV_0290 | Kaletra | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Real-time PCR | Decrease (1.06 Log10 Copies/GAPDH) | Approved, Investigational | 26198719 |
| DrugRepV_0291 | Kaletra | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Immunohistochemical assay | Decrease (>90 %) | Approved, Investigational | 26198719 |
| DrugRepV_0292 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Real-time PCR | Decrease (0.59 Log10 Copies/GAPDH) | Approved | 26198719 |
| DrugRepV_0293 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Immunohistochemical assay | Decrease (>90 %) | Approved | 26198719 |
| DrugRepV_0294 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Real-time PCR | Increase (0.15 Log10 Copies/GAPDH) | Approved, Investigational | 26198719 |
| DrugRepV_0295 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Immunohistochemical assay | No significant effect | Approved, Investigational | 26198719 |
| DrugRepV_1967 | Emetine Dihydrochloride Hydrate | Antiparasitic products, Insectisides and Repellents | Protozoal disease | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_1968 | Chloroquine Diphosphate | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1969 | Hydroxychloroquine Sulfate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1970 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1971 | Amodiaquine Dihydrochloride Dihydrate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1972 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1973 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1974 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1975 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1976 | Anisomycin | Antibacterial | Bacterial infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Experimental | 24841273 |
| DrugRepV_1977 | Cycloheximide | Antibacterial | Bacterial and fungal infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_1978 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1979 | Benztropine Mesylate | Nervous System | Parkinson disease | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1980 | Fluspirilene | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1981 | Thiothixene | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1982 | Fluphenazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1983 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1984 | Astemizole | Respiratory System | Allergies | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1985 | Chlorphenoxamine Hydrochloride | Respiratory System | Parkinson's | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1986 | Chlorpromazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1987 | Thiethylperazine Maleate | Respiratory System | Nausea | Vomiting | Mildly emetic cancer chemotherapy agents | Radiation therapy | Toxins | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Withdrawn | 24841273 |
| DrugRepV_1988 | Triflupromazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1989 | Clomipramine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1990 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1991 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1992 | Emetine Dihydrochloride Hydrate | Antiparasitic products, Insectisides and Repellents | Protozoal disease | Middle East respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_1993 | Chloroquine Diphosphate | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1994 | Hydroxychloroquine Sulfate | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1995 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1996 | Amodiaquine Dihydrochloride dihydrate | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1997 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1998 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1999 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_2000 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2001 | Anisomycin | Antibacterial | Bacterial infections | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Experimental | 24841273 |
| DrugRepV_2002 | Cycloheximide | Antibacterial | Bacterial and fungal infections | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_2003 | Benztropine Mesylate | Nervous System | Parkinson disease | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2004 | Fluspirilene | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_2005 | Thiothixene | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2006 | Fluphenazine Hydrochloride | Nervous System | Psychosis | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2007 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_2008 | Astemizole | Respiratory System | Allergies | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_2009 | Chlorphenoxamine Hydrochloride | Respiratory System | Parkinson's | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_2010 | Chlorpromazine Hydrochloride | Nervous System | Psychosis | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2011 | Triflupromazine Hydrochloride | Nervous System | Psychosis | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2012 | Clomipramine Hydrochloride | Nervous System | Psychosis | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2013 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2014 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (90 %) | Approved | 24841273 |
| DrugRepV_2035 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2036 | Chlorpromazine | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2037 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2038 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2039 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2040 | Chlorpromazine | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2041 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2042 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2043 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2044 | Chlorpromazine | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2045 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2046 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2047 | Cilnidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (60 %) | Approved | 24841269 |
| DrugRepV_2048 | Fluoxetine Hydrochloride | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Vet approved | 24841269 |
| DrugRepV_2049 | Manidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Investigational | 24841269 |
| DrugRepV_2050 | Oxybutynin | Genito Urinary System and Sex Hormones | Overactive bladder | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (80 %) | Approved, Investigational | 24841269 |
| DrugRepV_2051 | Pyrimethamine | Antiparasitic products, Insectisides and Repellents | Toxoplasmosis | Acute malaria | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | No significant decrease (20 %) | Approved, Investigational, Vet approved | 24841269 |
| DrugRepV_2052 | Rifabutin | Antiinfectives For Systemic Use | Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | No significant decrease (10 %) | Approved, Investigational | 24841269 |
| DrugRepV_2053 | Rifapentine | Antiinfectives For Systemic Use | Tuberculosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Investigational | 24841269 |
| DrugRepV_2066 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Severe acute respiratory syndrome coronavirus | NA | NA | Immunoblot assay | Decrease | Approved | 15215127 |
| DrugRepV_2067 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Severe acute respiratory syndrome coronavirus | NA | NA | Immunoflourescence assay | Decrease | Approved | 15215127 |
| DrugRepV_2068 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease | Approved | 15215127 |
| DrugRepV_3361 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immunosuppressant [treatment of transplant (kidney, liver, and heart) rejection], rheumatoid arthritis, severe psoriasis. | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell proliferation assay | Decrease (100 %) | Approved | 23620378 |
| DrugRepV_3362 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immunosuppressant [treatment of transplant (kidney, liver, and heart) rejection], rheumatoid arthritis, severe psoriasis. | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell proliferation assay | Decrease (80 %) | Approved | 23620378 |
| DrugRepV_3363 | Peg-interferon A-2b | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | HKU-39849 | NA | Cytopathic effect (CPE) assay | Decrease (100 %) | Approved | 23620378 |
| DrugRepV_3364 | Peg-interferon A-2b | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Middle East respiratory syndrome coronavirus | HKU-39849 | NA | Cytopathic effect (CPE) assay | Decrease (100 %) | Approved | 23620378 |
| DrugRepV_3375 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3376 | Mycophenolic Acid-Betaferon | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | NA | 24096239 |
| DrugRepV_3377 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3378 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3379 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3380 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3381 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3382 | Betaferon | NA | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (50 %) | Approved | 24096239 |
| DrugRepV_3383 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3384 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3385 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3386 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3387 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3388 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (90 %) | Approved | 24096239 |
| DrugRepV_3389 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3390 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3391 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3392 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3393 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3394 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (99 %) | Approved | 24096239 |
| DrugRepV_3395 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3396 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3397 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3398 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>2 Log) | Approved | 24096239 |
| DrugRepV_3399 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>1 Log) | Approved | 24096239 |
| DrugRepV_3400 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (>3 Log) | Approved | 24096239 |
| DrugRepV_3401 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (100 %) | Approved | 24096239 |
| DrugRepV_3402 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (100 %) | Approved | 24096239 |
| DrugRepV_3403 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (100 %) | Approved | 24096239 |
| DrugRepV_3404 | Intron A | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (76.2 %) | Approved | 24096239 |
| DrugRepV_3405 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (70.2 %) | Approved | 24096239 |
| DrugRepV_3406 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (66.6 %) | Approved | 24096239 |
| DrugRepV_3407 | SSYA10-001 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 24841268 |
| DrugRepV_3408 | SSYA10-001 | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 24841268 |
| DrugRepV_3624 | Benzodiazepine | Nervous System | Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease. | Severe acute respiratory syndrome coronavirus | Toronto-2 | NA | qRT-PCR | Decrease (50 %) | Approved, Investigational | 27654301 |
| DrugRepV_3651 | 2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Luciferase assay | Decrease (50 %) | NA | 21270170 |
| DrugRepV_3694 | BCX4430 | NA | Ebola virus | Middle East respiratory syndrome coronavirus | Jordan N3 | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_3695 | BCX4430 | NA | Ebola virus | Severe acute respiratory syndrome coronavirus | Urbani | NA | RT-PCR | Decrease (50 %) | Investigational | 24590073 |
| DrugRepV_4421 | N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (91.98 %) | NA | 24501399 |
| DrugRepV_4422 | N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (98.65 %) | NA | 24501399 |
| DrugRepV_4423 | 9H-carbazol-3-amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (42.29 %) | NA | 24501399 |
| DrugRepV_4424 | 7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (60.65 %) | NA | 24501399 |
| DrugRepV_4425 | N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (-0.15 %) | NA | 24501399 |
| DrugRepV_4426 | tris[4-(dimethylamino)phenyl]methanol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (82.15 %) | NA | 24501399 |
| DrugRepV_4427 | 6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (88.99 %) | NA | 24501399 |
| DrugRepV_4428 | 1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (24.06 %) | NA | 24501399 |
| DrugRepV_4429 | 2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (57.39 %) | NA | 24501399 |
| DrugRepV_4430 | N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (77.83 %) | NA | 24501399 |
| DrugRepV_4431 | 4-{[(5-methyl-2-thienyl)methyl]amino}phenol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (1.34 %) | NA | 24501399 |
| DrugRepV_4432 | N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (76.53 %) | NA | 24501399 |
| DrugRepV_4433 | N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (14.51 %) | NA | 24501399 |
| DrugRepV_4434 | 2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (8.55 %) | NA | 24501399 |
| DrugRepV_4435 | N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (79.93 %) | NA | 24501399 |
| DrugRepV_4436 | N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (69.24 %) | NA | 24501399 |
| DrugRepV_4437 | 4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (65.51 %) | NA | 24501399 |
| DrugRepV_4438 | N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (80.76 %) | NA | 24501399 |
| DrugRepV_4439 | N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (65.73 %) | NA | 24501399 |
| DrugRepV_4440 | N-(3-chlorophenyl)-N-(4-cyanophenyl)urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (78.34 %) | NA | 24501399 |
| DrugRepV_4441 | N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (52.46 %) | NA | 24501399 |
| DrugRepV_4442 | N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (24.34 %) | NA | 24501399 |
| DrugRepV_4443 | 4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (39.61 %) | NA | 24501399 |
| DrugRepV_4444 | 1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (44.31 %) | NA | 24501399 |
| DrugRepV_4445 | 2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (38.88 %) | NA | 24501399 |
| DrugRepV_4446 | N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (38.54 %) | NA | 24501399 |
| DrugRepV_4447 | 2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (50.22 %) | NA | 24501399 |
| DrugRepV_4448 | N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (51.28 %) | NA | 24501399 |
| DrugRepV_4449 | 4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (39.55 %) | NA | 24501399 |
| DrugRepV_4450 | N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (33.84 %) | NA | 24501399 |
| DrugRepV_4451 | 3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (23.55 %) | NA | 24501399 |
| DrugRepV_4452 | methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (77.79 %) | NA | 24501399 |
| DrugRepV_4453 | N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (56.45 %) | NA | 24501399 |
| DrugRepV_4454 | N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.55 %) | NA | 24501399 |
| DrugRepV_4455 | (1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (-3.09 %) | NA | 24501399 |
| DrugRepV_4456 | 4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (72.37 %) | NA | 24501399 |
| DrugRepV_4457 | N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.94 %) | NA | 24501399 |
| DrugRepV_4458 | 3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (53.23 %) | NA | 24501399 |
| DrugRepV_4459 | 5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (28.07 %) | NA | 24501399 |
| DrugRepV_4460 | 6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (25.6 %) | NA | 24501399 |
| DrugRepV_4461 | 2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (37.16 %) | NA | 24501399 |
| DrugRepV_4462 | N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (61.47 %) | NA | 24501399 |
| DrugRepV_4463 | 4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (66.62 %) | NA | 24501399 |
| DrugRepV_4464 | 2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (32.44 %) | NA | 24501399 |
| DrugRepV_4465 | 5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (30.53 %) | NA | 24501399 |
| DrugRepV_4466 | 2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (47.39 %) | NA | 24501399 |
| DrugRepV_4467 | 2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (49.81 %) | NA | 24501399 |
| DrugRepV_4468 | N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (51.17 %) | NA | 24501399 |
| DrugRepV_4469 | 8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (41.66 %) | NA | 24501399 |
| DrugRepV_4470 | N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | S, amino acids 674 to 683 | NA | CatL-Peptide cleavage | Decrease (40.85 %) | NA | 24501399 |
| DrugRepV_4519 | Alferon | NA | Condylomata acuminata | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 15200845 |
| DrugRepV_4520 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 15200845 |
| DrugRepV_4521 | Multiferon | Antineoplastic and Immunomodulating Agents | Hepatitis (viral, C) | Leukemia | Melanoma | Severe acute respiratory syndrome coronavirus | NA | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 15200845 |
| DrugRepV_4522 | IFN-alpha2a | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4523 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4524 | IFN-alphan1 | Antineoplastic and Immunomodulating Agents | Venereal or genital warts caused by the Human Papiloma Virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved, Investigational | 15200845 |
| DrugRepV_4525 | IFN-alphan3 | NA | Condylomata acuminata | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved, Investigational | 15200845 |
| DrugRepV_4526 | IFN-beta1a | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Condyloma acuminatum | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4527 | IFN-beta1b | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved | 15200845 |
| DrugRepV_4528 | Acyclovir | Dermatologicals; Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Herpes simplex, Zoster and varicella zoster) | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4529 | Ganciclovir | Antiinfectives For Systemic Use | Cytomegalovirus infection | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4530 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease (100 %) | Approved | 15200845 |
| DrugRepV_4531 | Indinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4532 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4533 | Saquinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved, Investigational | 15200845 |
| DrugRepV_4534 | Lamivudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Hepatitis B virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4535 | Zidovudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome/AIDS | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4536 | Oseltamivir | Antiinfectives For Systemic Use | Influenza A/B virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4537 | Zanamivir | Antiinfectives For Systemic Use | Influenza virus | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4538 | Amantadine | Nervous System | Influenza and Parkinson Disease | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4539 | Foscarnet | Antiinfectives For Systemic Use | Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | CPE inhibition assay | Decrease | Approved | 15200845 |
| DrugRepV_4540 | 1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 16451078 |
| DrugRepV_4541 | 1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 16451078 |
| DrugRepV_4542 | 1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 16451078 |
| DrugRepV_4543 | Alferon | NA | Condylomata acuminata | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 16451078 |
| DrugRepV_4544 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 15961169 |
| DrugRepV_4545 | AZT | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 15961169 |
| DrugRepV_4546 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 15961169 |
| DrugRepV_4547 | Aurintricarboxylic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 15961169 |
| DrugRepV_4548 | DS5000 | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 15961169 |
| DrugRepV_4549 | Novaron | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 15961169 |
| DrugRepV_4550 | Glycirrhizin | Bile And Liver Therapy | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 15961169 |
| DrugRepV_4551 | S-Nitroso-N-acetylpenicillamine | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 15961169 |
| DrugRepV_4552 | 7-(benzyloxy)-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4553 | 2-(3,4-dihydroxyphenyl)-7-[(2-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4554 | 7-[(2-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4555 | 7-[(2-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4556 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-iodophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4557 | 2-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4558 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-nitrophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4559 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-methylphenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4560 | 2-(3,4-dihydroxyphenyl)-7-[(3-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4561 | 7-[(3-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4562 | 7-[(3-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4563 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-iodophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4564 | 3-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4565 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-nitrophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4566 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methylphenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4567 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methoxyphenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4568 | 2-(3,4-dihydroxyphenyl)-7-[(4-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4569 | 7-[(4-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4570 | 7-[(4-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4571 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-iodophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4572 | 4-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4573 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-nitrophenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4574 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methylphenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4575 | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methoxyphenyl)methoxy]-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 22297745 |
| DrugRepV_4576 | Glycyrrhizin | Alimentary Tract and Metabolism | Chronic hepatitis | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Experimental | 15715493 |
| DrugRepV_4577 | Glycyrrhetinic Acid | NA | Apparent mineralocorticoid excess syndrome | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 15715493 |
| DrugRepV_4578 | (2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4579 | (2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4580 | (2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptame | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4581 | 6-{[(3S,6aR,6bS,8aS,11S,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-{[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-3,4-dihydroxy-N-[(2S)-4-methyl-1-oxopentan-2-yl]-5-[(3 | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4582 | butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13 | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4583 | methyl (2S)-2-(2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4584 | (4S)-4-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4585 | butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a, | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4586 | (2S,4aS,6aS,6bR,10S,12aS)-10-{[4,5-dihydroxy-6-(2-hydroxyacetyl)-3-{[3,4,5-trihydroxy-6-(2-hydroxyacetyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carbo | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4587 | (2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]-3-({3,4,5-trihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,1 | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4588 | 5-{6-[(2-{[(3S,6aR,6bS,8aS,11S,14bS)-11-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidi | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4589 | methyl (2S,4aS,6aS,6bR,10S,12aS)-10-({6-[(hydrazinecarbonyl)carbonyl]-3-({6-[(hydrazinecarbonyl)carbonyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b, | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4590 | methyl (2S,4aS,6aS,6bR,10S,12aS)-10-{[6-(2-azidoacetyl)-3-{[6-(2-azidoacetyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-ca | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4591 | 2-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4592 | 4-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-oxobutanoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | FFM1 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 15715493 |
| DrugRepV_4593 | 3-(benzyloxy)-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4594 | 3-[(2-chlorophenyl)methoxy]-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4595 | 3,7-bis[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4596 | 7-[(3-chlorophenyl)methoxy]-3-[(2,4-dichlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4597 | 7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(2-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4598 | 7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(3-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4599 | 2-[({6-[(3-chlorophenyl)methoxy]-5-hydroxy-4-oxo-1,4-dihydronaphthalen-2-yl}oxy)methyl]benzonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4600 | (2Z)-4-(3-{[(4-chlorophenyl)methyl]amino}phenyl)-2-hydroxy-4-oxobut-2-enoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4601 | 5,7-dihydroxy-3-[(3-nitrophenyl)methoxy]-2-phenyl-4H-chromen-4-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4602 | 3-{[(3,5-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy]methyl}benzonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | NA | 21925774 |
| DrugRepV_4603 | 1H-1,2,3-benzotriazol-1-yl 1H-indole-5-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4604 | 5-chloropyridin-3-yl 1H-indole-5-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4605 | 5-chloropyridin-3-yl 1-acetyl-1H-indole-5-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4606 | 5-chloropyridin-3-yl 1-(4-methylbenzenesulfonyl)-1H-indole-5-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4607 | 5-chloropyridin-3-yl 1-(3-nitrobenzenesulfonyl)-1H-indole-5-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4608 | 5-chloropyridin-3-yl1H-indole-6-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4609 | 5-chloropyridin-3-yl 1H-indole-4-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4610 | 5-chloropyridin-3-yl 1-acetyl-1H-indole-4-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4611 | 5-chloropyridin-3-yl 1H-indole-7-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4612 | 5-chloropyridin-3-yl (6R)-6-{[(tert-butoxy)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4613 | 5-chloropyridin-3-yl 2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | NA | Decrease (50 %) | NA | 18796354 |
| DrugRepV_4614 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 19853271 |
| DrugRepV_4615 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 19853271 |
| DrugRepV_4616 | Promazine | Nervous System | Psychomotor agitation | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Vet approved | 19853271 |
| DrugRepV_4617 | Promazine | Nervous System | Psychomotor agitation | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Vet approved | 19853271 |
| DrugRepV_4618 | Calpain VI inhibitor | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4619 | Calpain VI inhibitor | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4620 | Calpain IV inhibitor | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4621 | Calpain IV inhibitor | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4622 | Infergen | Anticancer | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 19853271 |
| DrugRepV_4623 | Infergen | Anticancer | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 19853271 |
| DrugRepV_4624 | Ampligen | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4625 | Ampligen | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4626 | UDA | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4627 | UDA | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4628 | EP128533 | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4629 | EP128533 | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 19853271 |
| DrugRepV_4630 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | No significant effect | Approved | 19853271 |
| DrugRepV_4631 | Ampligen | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | Increase | NA | 19853271 |
| DrugRepV_4632 | UDA | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | Increase | NA | 19853271 |
| DrugRepV_4633 | Cremaphor | NA | NA | Severe acute respiratory syndrome coronavirus | v2163 | NA | Survival assay | No significant effect | NA | 19853271 |
| DrugRepV_4634 | TG-0205221 | NA | SARS coronavirus | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 16884309 |
| DrugRepV_4635 | ethyl (2E,4S)-4-[(2S)-3-(4-fluorophenyl)-2-[(2S)-3-methyl-2-[(5-methyl-1,2-oxazol-3-yl)formamido]butanamido]propanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 16884309 |
| DrugRepV_4636 | ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-3-phenylpropanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 16884309 |
| DrugRepV_4637 | ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 16884309 |
| DrugRepV_4638 | ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(tert-butoxy)butanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 16884309 |
| DrugRepV_4639 | TG-0205221 | NA | SARS coronavirus | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (6.4 Log10) | NA | 16884309 |
| DrugRepV_4640 | TG-0205221 | NA | SARS coronavirus | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease | NA | 16884309 |
| DrugRepV_4641 | 5CI-IS-AC | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4642 | SPIII-5H | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4643 | SPIII-5Cl | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4644 | SPIII-5Br | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4645 | SPIII-5F | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4646 | SPIII-5Me | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4647 | SPIII-NA | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 20390088 |
| DrugRepV_4714 | Nutlin-3 | NA | NA | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 29795047 |
| DrugRepV_4715 | Hydroxyzine pamoate | Nervous System | Anxiety | Tension | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 29795047 |
| DrugRepV_4716 | Amodiaquine Dihydrochloride | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 29795047 |
| DrugRepV_4717 | Amodiaquine Dihydrochloride Dihydrate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 29795047 |
| DrugRepV_4718 | Chloroquine Diphosphate | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational, Vet approved | 29795047 |
| DrugRepV_4719 | Hydroxychloroquine Sulfate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 29795047 |
| DrugRepV_4720 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 29795047 |
| DrugRepV_4721 | Sotrastaurin | Anticancer | Uveal Melanoma | Richter Syndrome | Prolymphocytic Leukemia | Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 29795047 |
| DrugRepV_4722 | Acetophenazine Maleate | Nervous System | NA | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 29795047 |
| DrugRepV_4723 | Dosulepin Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 29795047 |
| DrugRepV_4724 | Methotrimeprazine Maleate Salt | NA | NA | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 29795047 |
| DrugRepV_4725 | N1-(4-pyridyl)-2-chloro-5-nitrobenzamide | NA | NA | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 29795047 |
| DrugRepV_4726 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease | Approved | 29566060 |
| DrugRepV_4727 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | No significant effect | Approved | 29566060 |
| DrugRepV_4728 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 29566060 |
| DrugRepV_4729 | L-NAME | NA | Hypotension | Spinal Cord Injury | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (15 %) | Investigational | 25487801 |
| DrugRepV_4730 | AG490 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (17 %) | NA | 25487801 |
| DrugRepV_4731 | PKC-412 | NA | Acute myeloid leukemia | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (33 %) | Approved, Investigational | 25487801 |
| DrugRepV_4732 | Ro 31-8220 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (73 %) | NA | 25487801 |
| DrugRepV_4733 | GF109203X | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (53 %) | NA | 25487801 |
| DrugRepV_4734 | SB203580 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (45 %) | NA | 25487801 |
| DrugRepV_4735 | U0126 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 25487801 |
| DrugRepV_4736 | Wortmannin | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (40 %) | Experimental | 25487801 |
| DrugRepV_4737 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (60 %) | Approved, Investigational | 25487801 |
| DrugRepV_4738 | Bay 11-7082 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (28 %) | NA | 25487801 |
| DrugRepV_4739 | GW5074 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 25487801 |
| DrugRepV_4740 | PP2 | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (23 %) | NA | 25487801 |
| DrugRepV_4741 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (93 %) | Approved, Investigational | 25487801 |
| DrugRepV_4742 | Everolimus | Antineoplastic and Immunomodulating Agents | Immune disorders | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (57 %) | Approved | 25487801 |
| DrugRepV_4743 | Dabrafenib | Antineoplastic and Immunomodulating Agents | Melanoma | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | Approved | 25487801 |
| DrugRepV_4744 | Selumetinib | Anticancer | Melanoma | Solid Tumour | Breast Cancer | Non Small Cell Lung Cancer | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (70 %) | Investigational | 25487801 |
| DrugRepV_4745 | Trametinib | Antineoplastic and Immunomodulating Agents | Thyroid cancer | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (95 %) | Approved | 25487801 |
| DrugRepV_4746 | Miltefosine | Antineoplastic and Immunomodulating Agents | Visceral leishmaniasis | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (28 %) | Approved | 25487801 |
| DrugRepV_4747 | tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4748 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4749 | 1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4750 | sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4751 | tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4752 | sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4753 | 4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4754 | sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4755 | tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4756 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4757 | ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4758 | sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4759 | tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4760 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4761 | 1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4762 | sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4763 | tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4764 | sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4765 | 4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4766 | sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4767 | tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4768 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4769 | ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4770 | sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4771 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4772 | sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4773 | 6-Mercaptopurine | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4774 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4775 | N-ethylmaleimide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Experimental | 25542975 |
| DrugRepV_4776 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 25542975 |
| DrugRepV_4777 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 24323636 |
| DrugRepV_4778 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (30 %) | Approved | 24323636 |
| DrugRepV_4779 | IFN-beta | Antineoplastic and Immunomodulating Agents | NA | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | NA | 24323636 |
| DrugRepV_4780 | IFN-alpha2a | Antineoplastic and Immunomodulating Agents | Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved, Investigational | 24323636 |
| DrugRepV_4781 | IFN-alpha2b | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Approved | 24323636 |
| DrugRepV_4782 | IFN-universal | NA | NA | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | NA | 24323636 |
| DrugRepV_4783 | IFN-gamma | Antineoplastic and Immunomodulating Agents | NA | Middle East respiratory syndrome coronavirus | Hu/Jordan-N3/2012 | NA | Virus yield reduction assay | Decrease (50 %) | NA | 24323636 |
| DrugRepV_4784 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4785 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4786 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4787 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4788 | 4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4789 | 4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4790 | 4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4791 | 4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4792 | 2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4793 | (4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4794 | 3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4795 | 3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4796 | 2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4797 | 2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4798 | 2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4799 | 2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4800 | 2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4801 | 2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4802 | 3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4803 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4804 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4805 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4806 | 2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4807 | 4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4808 | 4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4809 | 4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4810 | 4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4811 | 2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4812 | (4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4813 | 3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4814 | 3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4815 | 2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4816 | 2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4817 | 2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4818 | 2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4819 | 2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4820 | 2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4821 | 3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 27240464 |
| DrugRepV_4829 | Teicoplanin | Antiinfectives For Systemic Use | Bacterial infections | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved | 26953343 |
| DrugRepV_4830 | Dalbavancin | Antiinfectives For Systemic Use | Bacterial infections | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved | 26953343 |
| DrugRepV_4831 | Oritavancin | Antiinfectives For Systemic Use | Acute bacterial skin | Skin structure infections | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved | 26953343 |
| DrugRepV_4832 | Telavancin | Antiinfectives For Systemic Use | Skin infections (Bacterial) | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved | 26953343 |
| DrugRepV_4833 | 8-(trifluoromethyl)-9H-purin-6-amine | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4834 | 8-(trifluoromethyl)-9H-purin-6-amine | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4835 | 5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4836 | 2-methyl-5-[(methylamino)methyl]-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4837 | N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1R)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4838 | N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1S)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 25746232 |
| DrugRepV_4839 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4840 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}benzamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4841 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4842 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4843 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4844 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4845 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4846 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4847 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4848 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2,2-trifluoroacetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4849 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4850 | 2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4851 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4852 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methoxyacetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4853 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-3-methoxypropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4854 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4855 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4856 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4857 | 2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-(1H-1,2,3-triazol-1-yl)acetamido}phenyl)propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4858 | methyl 2-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-1H-pyrrole-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (31 %) | NA | 26190463 |
| DrugRepV_4859 | 2-(1H-1,2,3-benzotriazol-1-yl)-N-{[1,1-biphenyl]-4-yl}-N-[(thiophen-3-yl)methyl]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4860 | N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]-1H-imidazole-4-carboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (49 %) | NA | 26190463 |
| DrugRepV_4861 | 2-methyl-N-{4-[2-(4-phenyl-1H-1,2,3-triazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4862 | N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]furan-3-carboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (24 %) | NA | 26190463 |
| DrugRepV_4863 | 2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido}phenyl)propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_4864 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1-methyl-1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4865 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4866 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4867 | N-tert-butyl-2-(N-{2-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4868 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4869 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4870 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclobutanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4871 | N-tert-butyl-2-(N-{4-[(fluoromethoxy)methyl]phenyl}-2-(1H-indol-3-yl)acetamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4872 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}benzamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4873 | N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4874 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclopropanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4875 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4876 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4877 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4878 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4879 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-1,2-oxazole-5-carboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4880 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyrimidin-5-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4881 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4882 | N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4883 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4884 | 2-[N-(4-aminophenyl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4885 | (2S)-N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4886 | N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4887 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyrimidin-5-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 26190463 |
| DrugRepV_4888 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (26 %) | NA | 26190463 |
| DrugRepV_4889 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4890 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4891 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (34 %) | NA | 26190463 |
| DrugRepV_4892 | N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4893 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (53 %) | NA | 26190463 |
| DrugRepV_4894 | N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (49 %) | NA | 26190463 |
| DrugRepV_4895 | N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (48 %) | NA | 26190463 |
| DrugRepV_4896 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (47 %) | NA | 26190463 |
| DrugRepV_4897 | N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (43 %) | NA | 26190463 |
| DrugRepV_4898 | N-tert-butyl-2-{N-cyclopropyl-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (42 %) | NA | 26190463 |
| DrugRepV_4899 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrazin-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (41 %) | NA | 26190463 |
| DrugRepV_4900 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (41 %) | NA | 26190463 |
| DrugRepV_4901 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (41 %) | NA | 26190463 |
| DrugRepV_4902 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (41 %) | NA | 26190463 |
| DrugRepV_4903 | (2S)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (39 %) | NA | 26190463 |
| DrugRepV_4904 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridazin-4-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (35 %) | NA | 26190463 |
| DrugRepV_4905 | N-tert-butyl-2-[1-(3-methylfuran-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (36 %) | NA | 26190463 |
| DrugRepV_4906 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (34 %) | NA | 26190463 |
| DrugRepV_4907 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-2-(3-fluorophenyl)-N-phenylacetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (32 %) | NA | 26190463 |
| DrugRepV_4908 | N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (31 %) | NA | 26190463 |
| DrugRepV_4909 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (31 %) | NA | 26190463 |
| DrugRepV_4910 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(1H-pyrrol-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (31 %) | NA | 26190463 |
| DrugRepV_4911 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (30 %) | NA | 26190463 |
| DrugRepV_4912 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (29 %) | NA | 26190463 |
| DrugRepV_4913 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (29 %) | NA | 26190463 |
| DrugRepV_4914 | [(tert-butylcarbamoyl)(pyridin-3-yl)methyl](4-tert-butylphenyl)carbamic acid | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (29 %) | NA | 26190463 |
| DrugRepV_4915 | 2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (28 %) | NA | 26190463 |
| DrugRepV_4916 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (28 %) | NA | 26190463 |
| DrugRepV_4917 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (28 %) | NA | 26190463 |
| DrugRepV_4918 | N-tert-butyl-2-{N-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (28 %) | NA | 26190463 |
| DrugRepV_4919 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (28 %) | NA | 26190463 |
| DrugRepV_4920 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (27 %) | NA | 26190463 |
| DrugRepV_4921 | N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (27 %) | NA | 26190463 |
| DrugRepV_4922 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-chlorophenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (27 %) | NA | 26190463 |
| DrugRepV_4923 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-methylfuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (26 %) | NA | 26190463 |
| DrugRepV_4924 | N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (26 %) | NA | 26190463 |
| DrugRepV_4925 | N-tert-butyl-2-(4-tert-butylphenyl)-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (26 %) | NA | 26190463 |
| DrugRepV_4926 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (26 %) | NA | 26190463 |
| DrugRepV_4927 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(1H-indol-3-yl)acetamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4928 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4929 | N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4930 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(2-methylpropoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4931 | 2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (25 %) | NA | 26190463 |
| DrugRepV_4932 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (24 %) | NA | 26190463 |
| DrugRepV_4933 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (24 %) | NA | 26190463 |
| DrugRepV_4934 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-imidazol-4-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (24 %) | NA | 26190463 |
| DrugRepV_4935 | N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (24 %) | NA | 26190463 |
| DrugRepV_4936 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4937 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4938 | N-tert-butyl-2-(N-{2,6-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4939 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-methoxyacetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4940 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4941 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (23 %) | NA | 26190463 |
| DrugRepV_4942 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4943 | N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4944 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4945 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4946 | 2-(N-{[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4947 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (22 %) | NA | 26190463 |
| DrugRepV_4948 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4949 | N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4950 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4951 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(4-fluorophenyl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4952 | N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4953 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4954 | N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4955 | N-tert-butyl-2-[1-(furan-2-yl)-N-{4-[(1E)-2-phenylethenyl]phenyl}formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4956 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-2-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (21 %) | NA | 26190463 |
| DrugRepV_4957 | (2R)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-4-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4958 | N-tert-butyl-2-[N-(4-acetamidophenyl)-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4959 | 2-{N-[4-(butan-2-yloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4960 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4961 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-phenylacetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4962 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4963 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (20 %) | NA | 26190463 |
| DrugRepV_4964 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4965 | 2-[1-(1-benzofuran-3-yl)-N-(4-tert-butylphenyl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4966 | N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4967 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4968 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4969 | N-tert-butyl-2-[1-(furan-2-yl)-N-(4-phenoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4970 | 2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4971 | N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (19 %) | NA | 26190463 |
| DrugRepV_4972 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(oxolan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4973 | N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4974 | 2-[N-(4-aminophenyl)-2-(1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4975 | N-tert-butyl-2-(N-{2,3-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4976 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4977 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4978 | N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4979 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(3-methoxyphenoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4980 | N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4981 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4982 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4983 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4984 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4985 | 2-[N-(adamantan-1-yl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (18 %) | NA | 26190463 |
| DrugRepV_4986 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4987 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4988 | N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4989 | tert-butyl 2-(4-{N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]furan-2-amido}phenyl)-1H-pyrrole-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4990 | N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4991 | N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4992 | 2-[N-(4-aminophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4993 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4994 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4995 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4996 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (17 %) | NA | 26190463 |
| DrugRepV_4997 | N-tert-butyl-2-(N-{3-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_4998 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyrimidin-5-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_4999 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5000 | 2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5001 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(thiophen-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5002 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[5-(trifluoromethyl)furan-2-yl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5003 | N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5004 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5005 | N-tert-butyl-2-(N-{2,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5006 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5007 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5008 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5009 | 2-[N-(4-benzenesulfonamidophenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5010 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-1,2,3-triazol-4-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5011 | 2-(N-{bicyclo[2.2.1]heptan-2-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5012 | N-tert-butyl-2-{N-[4-(2-fluoropyridin-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (16 %) | NA | 26190463 |
| DrugRepV_5013 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5014 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyridin-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5015 | 2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5016 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5017 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5018 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5019 | N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5020 | N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5021 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5022 | N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (15 %) | NA | 26190463 |
| DrugRepV_5023 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5024 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5025 | N-tert-butyl-2-(N-{4-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5026 | N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)-2-methylpropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5027 | 2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5028 | 2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5029 | 2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5030 | N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5031 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyrimidin-5-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5032 | 2-[N-(4-aminophenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (14 %) | NA | 26190463 |
| DrugRepV_5033 | N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5034 | N-tert-butyl-2-[N-(4-methanesulfonamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5035 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrimidin-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5036 | N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5037 | N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yloxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5038 | N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5039 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5040 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-4-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5041 | N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]-N-(4-tert-butylphenyl)-3,3,3-trifluoropropanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (13 %) | NA | 26190463 |
| DrugRepV_5042 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-chlorofuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5043 | N-tert-butyl-2-{N-cyclopropyl-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5044 | N-tert-butyl-2-[N-(4-ethoxyphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5045 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-4-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5046 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5047 | N-tert-butyl-2-(N-{3,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5048 | N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methanesulfonamidophenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5049 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-2-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (12 %) | NA | 26190463 |
| DrugRepV_5050 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5051 | N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5052 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5053 | N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5054 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5055 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5056 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5057 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-5-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5058 | N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (11 %) | NA | 26190463 |
| DrugRepV_5059 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (10 %) | NA | 26190463 |
| DrugRepV_5060 | N-tert-butyl-2-[1-(furan-2-yl)-N-(4-propoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (10 %) | NA | 26190463 |
| DrugRepV_5061 | N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (10 %) | NA | 26190463 |
| DrugRepV_5062 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-imidazol-4-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (9 %) | NA | 26190463 |
| DrugRepV_5063 | 2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (9 %) | NA | 26190463 |
| DrugRepV_5064 | 2-[N-(4-benzylphenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (8 %) | NA | 26190463 |
| DrugRepV_5065 | N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)propanamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (8 %) | NA | 26190463 |
| DrugRepV_5066 | N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(6-methylpyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (8 %) | NA | 26190463 |
| DrugRepV_5067 | N-tert-butyl-2-[N-cyclohexyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (6 %) | NA | 26190463 |
| DrugRepV_5068 | Alisporivir | NA | Hepatitis C virus | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Virus yield reduction assay | Decrease (50 %) | Investigational | 27840112 |
| DrugRepV_5069 | Alisporivir | NA | Hepatitis C virus | Middle East respiratory syndrome coronavirus | N3/Jordan | NA | CPE inhibition assay | Decrease (50 %) | Investigational | 27840112 |
| DrugRepV_5070 | Alisporivir | NA | Hepatitis C virus | Severe acute respiratory syndrome coronavirus | MA-15 | NA | CPE inhibition assay | Decrease (50 %) | Investigational | 27840112 |
| DrugRepV_5309 | 1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5310 | diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5311 | diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5312 | 1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5313 | 2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5314 | 1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5315 | 1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5316 | {2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5317 | 4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5318 | 4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5319 | 4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5320 | 4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5321 | 4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5322 | 4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5323 | 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5324 | 1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5325 | 1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5326 | 1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Real-time PCR | Decrease (50 %) | NA | 15451189 |
| DrugRepV_5390 | Quinacrine | NA | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions | Middle East respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Investigational | 31307979 |
| DrugRepV_5473 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Experimental | 32020029 |
| DrugRepV_5474 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Approved | 32020029 |
| DrugRepV_5475 | Penciclovir | Antiinfectives For Systemic Use | Recurrent cold sores on the lips and face from Herpesvirus invections | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Approved | 32020029 |
| DrugRepV_5476 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Approved, Investigational, Vet approved | 32020029 |
| DrugRepV_5477 | Nafamostat | NA | Blood vessel coagulation | Hemorrhagic lesions | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Investigational | 32020029 |
| DrugRepV_5478 | Favipiravir | Antiviral | Influenza virus | SARS Coronavirus-2 | nCoV- 2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Investigational | 32020029 |
| DrugRepV_5479 | Beta-D-N4-hydroxycytidine | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (50 %) | NA | 31578288 |
| DrugRepV_5503 | Cepharanthine | Antiinflammatory and antineoplastic | Inflammatory disorders/Cancer | SARS Coronavirus-2 | GX_P2V/pangolin/2017/Guangxi | NA | qRT-PCR | Decrease (50 %) | NA | 32149769 |
| DrugRepV_5504 | Selamectin | Antiparasitic | Vet-Antihelminthic | SARS Coronavirus-2 | GX_P2V/pangolin/2017/Guangxi | NA | qRT-PCR | Decrease | Vet approved | 32149769 |
| DrugRepV_5505 | Mefloquine hydrochloride | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | GX_P2V/pangolin/2017/Guangxi | NA | qRT-PCR | Decrease | Approved, Investigational | 32149769 |
| DrugRepV_5531 | JQ1 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5532 | RVX-208 | NA | Diabetes, Atherosclerosis, and Coronary Artery Disease | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5533 | Silmitasertib | NA | Medulloblastoma | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5534 | TMCB | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5535 | Apicidin | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5536 | Valproic Acid | Nervous System | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5537 | Bafilomycin A1 | Antibiotics | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Experimental | 32353859 |
| DrugRepV_5538 | E-52862 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5539 | PD-144418 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5540 | RS-PPCC | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5541 | PB28 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5542 | Haloperidol | Nervous System | Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5543 | Entacapone | Nervous System | Parkinson Disease | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5544 | Indomethacin | Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System | Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5545 | Metformin | Alimentary Tract and Metabolism | Diabetes | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5546 | Ponatinib | Antineoplastic and Immunomodulating Agentss | Chronic myeloid leukemia | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5547 | H-89 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5548 | Merimepodib | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5549 | Migalastat | Alimentary Tract and Metabolism | Fabry disease | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5550 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5551 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5552 | XL413 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5553 | CCT 365623 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5554 | Midostaurin | Antineoplastic and Immunomodulating Agentss | Acute myeloid leukemia (AML) | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5555 | Ruxolitinib | Antineoplastic and Immunomodulating Agentss | Bone marrow cancer | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5556 | ZINC1775962367 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5557 | ZINC4326719 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5558 | ZINC4511851 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5559 | ZINC95559591 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5560 | AC-55541 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5561 | AZ8838 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5562 | Daunorubicin | Antineoplastic and Immunomodulating Agentss | Cancer | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5563 | GB110 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5564 | S-verapamil | NA | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5565 | AZ3451 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5566 | ABBV-744 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5567 | dBET6 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5568 | MZ1 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5569 | CPI-0610 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5570 | Sapanisertib | NA | Tumor | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5571 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5572 | Zotatifin | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5573 | Verdinexor | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5574 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5575 | Dabrafenib | Antineoplastic and Immunomodulating Agents | Melanoma | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5576 | WDB002 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5577 | Sanglifehrin A | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Experimental | 32353859 |
| DrugRepV_5578 | FK-506 | Dermatologicals; Antineoplastic and Immunomodulating Agents | Liver transplantation | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5579 | Pevonedistat | NA | Lymphoma | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5580 | Ternatin 4 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5581 | 4E2RCat | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5582 | Tomivosertib | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5583 | (2R,5S,11S,14S,17R,18R,21E)-2-(2-aminoethyl)-18-methoxy-11,17-dimethyl-14-(propan-2-yl)-3-oxa-9,12,15,28-tetraazatricyclo[21.3.1.1?,?]octacosa-1(26),21,23(27),24-tetraene-4,10,13,16-tetrone | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5584 | N-(5-{3-[(4-Hydroxyphenyl)sulfamoyl]-4-methoxyphenyl}-4-methyl-1,3-thiazol-2-yl)-2,2-dimethylpropanamide | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5585 | PS3061 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5586 | IHVR-19029 | NA | NA | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | NA | 32353859 |
| DrugRepV_5587 | Captopril | Cardiovascular agents | Hypertension | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5588 | Lisinopril | Cardiovascular agents | Hypertension | Congestive heart failure | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_5589 | Camostat | Blood and Blood Forming Organs | Pancreatitis | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Experimental | 32353859 |
| DrugRepV_5590 | Nafamostat | NA | Blood vessel coagulation | Hemorrhagic lesions | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Investigational | 32353859 |
| DrugRepV_5591 | Chloramphenicol | Antiinfectives For Systemic Use | Bacterial infections | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5592 | Tigecycline | Antiinfectives For Systemic Use | Complicated skin and skin structure infections | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved | 32353859 |
| DrugRepV_5593 | Linezolid | Antiinfectives For Systemic Use | Bacterial infections | SARS Coronavirus-2 | 2019-nCoV/USA-WA1/2020 | NA | NA | Decrease (50 %) | Approved, Investigational | 32353859 |
| DrugRepV_7534 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32150618 |
| DrugRepV_7535 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32150618 |
| DrugRepV_7536 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7537 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7538 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7539 | Digoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7540 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7541 | Digitoxin | Cardiovascular agents | Arrhythmia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7542 | Emetine | Antiparasitic products, Insecticides and Repellents | NA | SARS Coronavirus-2 | BetaCoV/Hong Kong/VM20001061/2020 | NA | TCID50 assay/ qRT-PCR | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7543 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7544 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7545 | Indomethacin | Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System | Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis | SARS Coronavirus-2 | cDNA used to create pseudotyped virus, GenBank: MN908947.3 | NA | Luciferase labelled | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7546 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7547 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7548 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7549 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7550 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7551 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7552 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | SARS Coronavirus-2 | Wuhan/WIV04/2020 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7553 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | SARS Coronavirus-2 | Wuhan/WIV04/2020 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7554 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7555 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7556 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7557 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7558 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52286 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7559 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | SARS Coronavirus-2 | BetaCoV/Hong Kong/VM20001061/2020 | NA | TCID50 assay/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7560 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Brazil/RJ-314/2020 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7561 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Brazil/RJ-314/2020 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7562 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7563 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7564 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7565 | Bazedoxifene | Genito Urinary System and Sex Hormones | Postmenopausal osteoporosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7566 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7567 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7568 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7569 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7570 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | C-Tan-nCoV Wuhan strain 01 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7571 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7572 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7573 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7574 | Alprostadil | Genito Urinary System and Sex Hormones | Palliative and erectile dysfunction | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7575 | Merimepodib | NA | NA | SARS Coronavirus-2 | SARS-CoV-2 USA-WA1/2020 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7576 | Merimepodib | NA | NA | SARS Coronavirus-2 | SARS-CoV-2 USA-WA1/2020 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7577 | Opipramol | Nervous System | Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7578 | Opipramol | Nervous System | Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7579 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52281 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7580 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52281 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7581 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7582 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7583 | Amodiaquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52282 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7584 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | SARS Coronavirus-2 | Australia/VIC01/2020 isolate) | NA | RT-PCR | Decrease (50 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7585 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | SARS Coronavirus-2 | Australia/VIC01/2020 isolate) | NA | RT-PCR | Decrease (90 %) | Approved, Investigational, Vet approved | 32438446 |
| DrugRepV_7586 | Fluspirilene | Nervous System | Schizophrenia | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52289 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7587 | Fluspirilene | Nervous System | Schizophrenia | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52289 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7588 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7589 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7590 | Clomipramine | Nervous System | Depression, schizophrenia, Tourette disorder | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52287 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7591 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7592 | Hydroxyprogesterone | Genito Urinary System And Sex Hormones | Reduces the rate of recurrent preterm birth | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7593 | Baricitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52283 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7594 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52291 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7595 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52291 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7596 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52281 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7597 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52281 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7598 | Promethazine | Dermatologicals | Rhinitis, allergic conjunctivitis, allergic reactions, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness. | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52292 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7599 | Promethazine | Dermatologicals | Rhinitis, allergic conjunctivitis, allergic reactions, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness. | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52292 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7600 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7601 | Abemaciclib | Antineoplastic And Immunomodulating Agents | Cancer | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7602 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7603 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7604 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7605 | Eltrombopag | Blood and Blood Forming Organs | Idiopathic thrombocytopenic purpura (ITP) | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7606 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7607 | Gilteritinib | Antineoplastic and Immunomodulating Agents | Relapsed or refractory acute myeloid leukaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7608 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7609 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Cytopathic effect (CPE) assay | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7610 | Camostat | Blood and Blood Forming Organs | Pancreatitis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7611 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7612 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7613 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | Wuhan/WIV04/2023 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7614 | Fluphenazine | Nervous System | Psychosis | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52288 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7615 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52290 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7616 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52290 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7617 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2 (?CoV/KOR/KCDC03/2020 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7618 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52293 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7619 | Tamoxifen | Antineoplastic and Immunomodulating Agents | Breast cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52293 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7620 | Umifenovir | Antiinfectives For Systemic Use | Prophylaxis/treatment of influenza in Russia and China | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7621 | Umifenovir | Antiinfectives For Systemic Use | Prophylaxis/treatment of influenza in Russia and China | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7622 | Anidulafungin | Antiinfectives For Systemic Use | Invasive candidiasis/candidaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7623 | Anidulafungin | Antiinfectives For Systemic Use | Invasive candidiasis/candidaemia | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7624 | Benztropine | Nervous System | Parkinson disease | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52284 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7625 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7626 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7627 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7628 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7629 | Saquinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7630 | Saquinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7631 | Oxprenolol | Cardiovascular System | Hypertension, angina pectoris, arrhythmias, and anxiety. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7632 | Oxprenolol | Cardiovascular System | Hypertension, angina pectoris, arrhythmias, and anxiety. | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7633 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7634 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7635 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7636 | Atazanavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7637 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52294 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7638 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52294 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7639 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2019 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32438446 |
| DrugRepV_7640 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2019 | NA | Immunofluorescence | Decrease (90 %) | Experimental | 32438446 |
| DrugRepV_7641 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7642 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020 | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7643 | Tipranavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7644 | Tipranavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved, Investigational | 32438446 |
| DrugRepV_7645 | Dolutegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7646 | Dolutegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7647 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7648 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Cytopathic effect (CPE) assay | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7649 | Favipiravir | Antiviral | Influenza virus | SARS Coronavirus-2 | Wuhan/WIV04/2019 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Investigational | 32438446 |
| DrugRepV_7650 | Favipiravir | Antiviral | Influenza virus | SARS Coronavirus-2 | Wuhan/WIV04/2019 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Investigational | 32438446 |
| DrugRepV_7651 | Sulfadoxine | Antiparasitic | Malaria | SARS Coronavirus-2 | BavPat1 | NA | RT-PCR | Decrease (50 %) | Approved, Investigational | 32438446 |
| DrugRepV_7652 | Amprenavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7653 | Amprenavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7654 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52285 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7655 | Penciclovir | Antiinfectives For Systemic Use | Recurrent cold sores on the lips and face from Herpesvirus invections | SARS Coronavirus-2 | Wuhan/WIV04/2019 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7656 | Penciclovir | Antiinfectives For Systemic Use | Recurrent cold sores on the lips and face from Herpesvirus invections | SARS Coronavirus-2 | Wuhan/WIV04/2019 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7657 | Darunavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7658 | Darunavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7659 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7660 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | SARS Coronavirus-2 | Wuhan/WIV04/2022 | NA | qRT-PCR/ NP expression/Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7661 | Indinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7662 | Indinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | RT-PCR | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7663 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32344449 |
| DrugRepV_7664 | Cetilistat | NA | Obesity | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Investigational | 32473310 |
| DrugRepV_7665 | Diiodohydroxyquinoline | Genito Urinary System And Sex Hormones | Used in the treatment of amoebiasis. | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7666 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7667 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32473310 |
| DrugRepV_7668 | Cetilistat | NA | Obesity | SARS Coronavirus-2 | | NA | Viral load reduction assay | Decrease (90 %) | Investigational | 32473310 |
| DrugRepV_7669 | Diiodohydroxyquinoline | Genito Urinary System And Sex Hormones | Used in the treatment of amoebiasis. | SARS Coronavirus-2 | | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7670 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7671 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | Viral load reduction assay | Decrease (90 %) | Approved | 32473310 |
| DrugRepV_7672 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32511355 |
| DrugRepV_7673 | ROC-325 | NA | NA | SARS Coronavirus-2 | | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 32511355 |
| DrugRepV_7674 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 32511355 |
| DrugRepV_7675 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32511355 |
| DrugRepV_7676 | Hycanthone | Antischistosomal | Parasitic infections | SARS Coronavirus-2 | | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Experimental | 32511355 |
| DrugRepV_7677 | Clomipramine | Nervous System | Depression, schizophrenia, Tourette disorder | SARS Coronavirus-2 | | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32511355 |
| DrugRepV_7678 | Amiodarone | Cardiovascular agents | Anginal and Arrhythmia | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7679 | Bosutinib | Antineoplastic and Immunomodulating Agents | Cancer | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7680 | Clofazamine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7681 | Domperidone | Alimentary Tract and Metabolism | Dyspepsia, heartburn, epigastric pain | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7682 | Entecavir | Antiinfectives For Systemic Use | Hepatitis B virus | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7683 | Fedratinib | Antineoplastic And Immunomodulating Agents | Myelofibrosis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7684 | Gilteritinib | Antineoplastic And Immunomodulating Agents | Acute myeloid leukemia | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7685 | Ipratropium bromide | Respiratory System | Asthma | Chronic bronchitis | Emphysema | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Experimental | 32577649 |
| DrugRepV_7686 | Lomitapide | Cardiovascular system | Hypercholesterolemia | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7687 | Metoclopramide | Alimentary Tract and Metabolism | Diabetic gastroparesis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577649 |
| DrugRepV_7688 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7689 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Experimental | 32577649 |
| DrugRepV_7690 | S1RA | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32577649 |
| DrugRepV_7691 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7692 | Verapamil | Cardiovascular agents | Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders). | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577649 |
| DrugRepV_7693 | Z-FA-FMK | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32577649 |
| DrugRepV_7694 | Lactoferrin | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32577649 |
| DrugRepV_7695 | Nafamostat | NA | Blood vessel coagulation | Hemorrhagic lesions | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Investigational | 32532094 |
| DrugRepV_7696 | Immunoglobulin F(ab’)2 | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32659292 |
| DrugRepV_7697 | Unfractionated Heparin | NA | Prophylaxis and Venous thrombosis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Investigational | 32577638 |
| DrugRepV_7698 | UFH-de6S | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32577638 |
| DrugRepV_7699 | Enoxaparin | Blood And Blood Forming Organs | Deep vein thrombosis | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved | 32577638 |
| DrugRepV_7700 | Enoxaparin-de6S | NA | NA | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | NA | 32577638 |
| DrugRepV_7701 | Pegasys | NA | Hepatitis C Virus | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 32532085 |
| DrugRepV_7702 | Avonex | Antineoplastic and Immunomodulating Agents | Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7703 | Rebif | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7704 | Betaferon | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7705 | Immukin | NA | Chronic granulomatous disease and Osteopetrosis | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved, Investigational | 32532085 |
| DrugRepV_7706 | 25-Hydroxycholesterol | NA | NA | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Experimental | 32532085 |
| DrugRepV_7707 | AM580 | NA | NA | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | NA | 32532085 |
| DrugRepV_7708 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | | NA | Plaque reduction assay | Decrease (50 %) | Approved | 32532085 |
| DrugRepV_7709 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | Plaque reduction assay | Decrease (50 %) | Experimental | 32532085 |
| DrugRepV_7710 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7711 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7712 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7713 | DS-6930 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7714 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7715 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7716 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7717 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7718 | R 82913 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7719 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7720 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7721 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7722 | YH-1238 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7723 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7724 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7725 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7726 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7727 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7728 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7729 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7730 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7731 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7732 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7733 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7734 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7735 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7736 | 8-(2-Chlorostyryl)caffeine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7737 | AMG-2674 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7738 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7739 | Elopiprazole | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7740 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7741 | KW 8232 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7742 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7743 | N-tert-Butylisoquine | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7744 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7745 | SDZ-62-434 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7746 | YH-1238 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7747 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7748 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7749 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7750 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7751 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7752 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7753 | SL-11128 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7754 | Clofazimine | Antiinfectives For Systemic Use | Lepromatous leprosy | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Approved | 32707573 |
| DrugRepV_7755 | DS-6930 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7756 | R 82913 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Experimental | 32707573 |
| DrugRepV_7757 | Hanfangchin A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7758 | SB-616234A | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7759 | MLN-3897 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7760 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7761 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7762 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7763 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7764 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7765 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7766 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Investigational | 32707573 |
| DrugRepV_7767 | VBY-825 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7768 | ONO 5334 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7769 | Z LVG CHN2 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7770 | MDL 28170 | NA | NA | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | NA | 32707573 |
| DrugRepV_7771 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Experimental | 32687696 |
| DrugRepV_7772 | Favipiravir | Antiviral | Influenza virus | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Investigational | 32687696 |
| DrugRepV_7773 | Galidesivir | NA | Ebolavirus | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Investigational | 32687696 |
| DrugRepV_7774 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved, Investigational | 32687696 |
| DrugRepV_7775 | Camostat mesylate | NA | Pancreatitis | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Experimental | 32687696 |
| DrugRepV_7776 | Nafamostat Mesylate | NA | Blood vessel coagulation | Hemorrhagic lesions | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Investigational | 32687696 |
| DrugRepV_7777 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32687696 |
| DrugRepV_7778 | Apilimod | NA | Crohn's disease | Psoriasis | Psoriatic disorders | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Investigational | 32687696 |
| DrugRepV_7779 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32687696 |
| DrugRepV_7780 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32687696 |
| DrugRepV_7781 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Approved | 32687696 |
| DrugRepV_7782 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | nCoV-2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Approved | 32194981 |
| DrugRepV_7783 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | nCoV-2019BetaCoV/Wuhan/WIV04/2019 | NA | qRT-PCR | Decrease (50 %) | Approved | 32194981 |
| DrugRepV_7784 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | LC-MS/MS | Decrease (50 %) | Experimental | 32589775 |
| DrugRepV_7785 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | NA | NA | LC-MS/MS | Decrease (50 %) | Experimental | 32589775 |
| DrugRepV_7786 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | SARS Coronavirus-2 | SARS-CoV-2/Leiden-0002 | NA | qRT-PCR | Decrease (50 %) | Investigational | 32513797 |
| DrugRepV_7787 | Auranofin | Musculo-Skeletal System | Rheumatoid arthritis | SARS Coronavirus-2 | USA-WA1/2020 | NA | qRT-PCR | Decrease (50 %) | Approved | 32442105 |
| DrugRepV_7788 | SSAA09E3 | NA | NA | Severe acute respiratory syndrome coronavirus | Toronto-2 | NA | Dose-dependence fluorescence inhibition assay | Decrease (50 %) | NA | 23678171 |
| DrugRepV_7789 | SSAA09E1 | NA | NA | Severe acute respiratory syndrome coronavirus | Toronto-2 | NA | Dose-dependence fluorescence inhibition assay | Decrease (50 %) | NA | 23678171 |
| DrugRepV_7790 | SSAA09E2 | NA | NA | Severe acute respiratory syndrome coronavirus | Toronto-2 | NA | Dose-dependence fluorescence inhibition assay | Decrease (50 %) | NA | 23678171 |
| DrugRepV_7791 | Ferruginol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Cell based assay | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7792 | Dehydroabieta-7-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7793 | Cryptojaponol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7794 | 8beta-hydroxyabieta-9(11),13- dien-12-one | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7795 | 7beta-hydroxydeoxycryptojaponol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7796 | 6,7-dehydroroyleanone | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7797 | 3beta,12-diacetoxyabieta-6,8,11,13- tetraene | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7798 | Pinusolidic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7799 | Forskolin | NA | Smooth muscle relaxant | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Experimental, Investigational | 17663539 |
| DrugRepV_7800 | Cedrane-3beta,12-diol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7801 | alpha-cadinol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7802 | Betulinic acid | NA | Dysplastic Nevus Syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Investigational | 17663539 |
| DrugRepV_7803 | Betulonic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7804 | Hinokinin | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7805 | Savinin | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7806 | Honokiol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7807 | Magnolol | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17663539 |
| DrugRepV_7808 | Curcumin | NA | Depressive disorder | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 17663539 |
| DrugRepV_7809 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Approved | 17663539 |
| DrugRepV_7810 | Valinomycin | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | Experimental | 17663539 |
| DrugRepV_7811 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational, Vet approved | 32725286 |
| DrugRepV_7812 | Tizoxanide | Antiparasitic products, Insectisides and Repellents | Crytosporidiosis and Giardiasis | Middle East respiratory syndrome coronavirus | NA | NA | Luciferase assay | Decrease (50 %) | Approved, Investigational, Vet approved | 32725286 |
| DrugRepV_7813 | 2-aminobenzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | Experimental | 16638531 |
| DrugRepV_7814 | 2-(5-bromopyridin-3-yl)-1-[5-(4-chlorophenyl)furan-2-yl]-2-fluoroethanone | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 18295820 |
| DrugRepV_7815 | ML188 | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Luminescent Cell Viability Assay | Decrease (50 %) | NA | 23231439 |
| DrugRepV_7816 | ML300 | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7817 | 2-(benzotriazol-1-yl)-N-(4-phenylphenyl)-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7818 | 5-Chloro-pyridin-3-yl Furan-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7819 | 5-Chloropyridin-3-yl Benzofuran-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7820 | 5-Bromo-pyridin-3-yl Furan-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7821 | 5-Chloro-pyridin-3-yl-1H-indole-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7822 | 5-Chloropyridin-3-yl-benzo-(b)-thiophene-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7823 | 5-Chloropyridin-3-yl-thiazole-4-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7824 | 5-Chloropyridin-3-yl-3-methoxybenzoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7825 | 5-Chloropyridin-3-yl-5-(4-chlorophenyl)furan-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric assay | Decrease (50 %) | NA | 17381079 |
| DrugRepV_7826 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]propanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7827 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-2-methylpropanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7828 | N-{4-[(1H-Benzotriazol-1-ylacetyl)(3-thienylmethyl)amino]phenyl}-2,2-dimethylpropanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7829 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-3-methoxypropanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7830 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclobutanecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7831 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclohexanecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7832 | N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]benzamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7833 | 2-methylpropyl N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7834 | 2-(benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7835 | 2-(benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7836 | 2-(benzotriazol-1-yl)-N-(4-pyridin-3-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7837 | 2-(benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7838 | 2-(benzotriazol-1-yl)-N-(4-pyridin-4-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7839 | 2-(benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 24080461 |
| DrugRepV_7840 | benzyl N-[(2S)-1-[[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[(4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl)amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7841 | (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-phenylmethoxybutanoyl]amino]-4-methylpentanoyl]amino]-N,N-dimethyl-6-(5-nitro-1,4-dioxo-3H-phthalazin-2-yl)-5-oxohexanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7842 | methyl (E,4S)-4-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]pentanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7843 | ethyl 3-[(3-amino-3-oxopropyl)-[[(2R,5S)-2-benzyl-7-methyl-4-oxo-5-(phenylmethoxycarbonylamino)octanoyl]amino]carbamoyl]oxirane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7844 | (2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]propanoyl]amino]-N-[(2S)-3-cyclohexyl-1-[[(2S)-1-(1H-imidazol-5-yl)-3-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-methylbutanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7845 | N-[(Benzyloxy)carbonyl]valyl-N-[1-oxo-3-(2-oxo-3-pyrrolidinyl)-1-(1,3-thiazol-2-yl)-2-propanyl]leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7846 | N-[(Benzyloxy)carbonyl]-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-D-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7847 | N-{[3-(Dimethylamino)phenoxy]acetyl}-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7848 | 2-[2,3-Dichloro-4-(2-methylenebutanoyl)phenoxy]-N-(2-methyl-2-propanyl)acetamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7849 | Cinanserin | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7850 | 5-Chloro-3-pyridinyl 1H-indole-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7851 | 1-(2-Naphthylmethyl)-2,3-dioxo-5-indolinecarboxamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7852 | 1-[(1H-Indol-5-ylcarbonyl)oxy]-1H-benzotriazole | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7853 | 4-(4-Chlorophenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydro-5-pyrimidinecarbonitrile | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7854 | 4-{(Z)-[1-(4-Fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene]methyl}benzoic acid | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7855 | 3-Benzyl-1-[(6,7-dimethyl-2-oxo-1,2-dihydro-3-quinolinyl)methyl]-1-[2-(2-methylphenyl)ethyl]urea | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7856 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-(3-methylbutanoyl)-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7857 | tert-butyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7858 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7859 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxohexan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7860 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7861 | Benzyl [(2S,3R)-1-({(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}amino)-3-methyl-1-oxo-2-pentanyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7862 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7863 | benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7864 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenylacetyl)amino]pentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7865 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyphenyl)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7866 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[3-(4-methoxyphenyl)propanoylamino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7867 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-[3-(3-pyridinyl)propanoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7868 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-phenyl-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7869 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7870 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(3,4-dimethoxyphenyl)-2-propenoyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7871 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenoxyacetyl)amino]pentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7872 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(4-methoxyphenoxy)acetyl]-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7873 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7874 | N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-{[3-(dimethylamino)phenoxy]acetyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7875 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7876 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(3-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7877 | (2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(2-methoxyanilino)acetyl]amino]-4-methylpentanamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease (50 %) | NA | 23747811 |
| DrugRepV_7878 | benzyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(5-phenyl-1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7879 | N~2~-[(Benzyloxy)carbonyl]-N-{(2S)-1-[5-(4-methylphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7880 | benzyl N-[(2S)-1-[[(2S)-1-[5-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7881 | benzyl N-[(2S)-1-[[(2S)-1-[5-(2-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | Fluorometric protease inhibitory assay | Decrease | NA | 23747811 |
| DrugRepV_7882 | 5-chloropyridin-3-yl 5-(4-chlorophenyl)oxolane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7883 | 5-chloropyridin-3-yl 5-(4-nitrophenyl)oxolane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7884 | 5-chloropyridin-3-yl 5-(4-chloro-2-nitrophenyl)oxolane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7885 | 5-chloropyridin-3-yl 5-(2-nitrophenyl)oxolane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7886 | 5-chloropyridin-3-yl 5-(3-nitrophenyl)oxolane-2-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7887 | (5-chloropyridin-3-yl) pyridine-4-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7888 | (5-chloropyridin-3-yl) pyridine-3-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7889 | (5-chloropyridin-3-yl) 4-chlorobenzoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7890 | (5-chloropyridin-3-yl) 2-nitrobenzoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7891 | (5-chloropyridin-3-yl) 3-nitrobenzoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7892 | 5-Chloro-3-pyridinyl 1-naphthoate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_7893 | (5-chloropyridin-3-yl) 2-oxochromene-3-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | NA | Decrease (50 %) | NA | 17931870 |
| DrugRepV_8323 | Alisporivir | NA | Hepatitis C virus | SARS Coronavirus-2 | Experimental | NA | Viral RNA reduction assay | Decrease (50 %) | Investigational | 32376613 |
| DrugRepV_8324 | Alisporivir | NA | Hepatitis C virus | SARS Coronavirus-2 | Experimental | NA | Viral RNA reduction assay | Decrease (90 %) | Investigational | 32376613 |
| DrugRepV_8325 | Remdesivir | Antiviral | Hepatitis C | Ebola | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Experimental | 32429580 |
| DrugRepV_8326 | Tenofovir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 32429580 |
| DrugRepV_8327 | 4-ethynyl-2-fluoro-2-deoxyadenosine | NA | NA | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 32429580 |
| DrugRepV_8328 | Alovudine | NA | HIV | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 32429580 |
| DrugRepV_8329 | 5-O-(12-thioethydodecanoyl)FLT | NA | NA | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 32429580 |
| DrugRepV_8330 | Lamivudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Hepatitis B virus | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32429580 |
| DrugRepV_8331 | 5-O-(tetradecanoyl)3TC | NA | NA | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 32429580 |
| DrugRepV_8332 | Emtricitabine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved | 32429580 |
| DrugRepV_8333 | 5-O-(tetradecanoyl)FTC | NA | NA | SARS Coronavirus-2 | Experimental | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 32429580 |
| DrugRepV_8334 | Hydroxychloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | SARS Coronavirus-2 | Experimental | NA | Viral inhibition assay | Decrease (50 %) | Approved | 32285930 |
| DrugRepV_8335 | Nafamostat | NA | Blood vessel coagulation | Hemorrhagic lesions | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Investigational | 32596694 |
| DrugRepV_8336 | Camostat | Blood And Blood Forming Organs | Chronic pancreatitis | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Experimental | 32596694 |
| DrugRepV_8337 | Gabexate | NA | Cancer, ischemia-reperfusion injury, and pancreatitis | SARS Coronavirus-2 | NA | NA | NA | Decrease (50 %) | Investigational | 32596694 |
| DrugRepV_8338 | Nelfinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | SARS Coronavirus-2 | NA | NA | NA | Decrease (100 %) | Approved | 32374457 |